高病毒载量慢性乙型肝炎孕妇口服核苷(酸)类抗病毒药母婴阻断的有效性和安全性

肝脏 ›› 2023, Vol. 28 ›› Issue (3): 296-298.

高病毒载量慢性乙型肝炎孕妇口服核苷(酸)类抗病毒药母婴阻断的有效性和安全性

梁蘅恺, 韦璐, 苏明华, 梁焕, 胡伯斌, 黄建芳, 陈艳红, 江建宁

530021 南宁广西医科大学第一附属医院感染性疾病科教育部区域性高发肿瘤早期防治研究重点实验室

收稿日期:2022-08-27 出版日期:2023-03-31 发布日期:2023-08-28
通讯作者: 江建宁,Email:jjianning@163.com
基金资助:
国家自然科学基金(81960115);广西病毒性肝炎防治研究重点实验室开放课题基金(GXCDCKL202001);教育部区域性高发肿瘤早期防治研究重点实验室自主课题(GKE2019-04);广西医科大学青年科学基金(GXMUYSF201910)

Clinical study on the efficacy and safety of oral nucleos(t)ide analogues in HBV mother-to-infant obstruction of pregnant women with high viral load

LIANG Heng-kai, WEI Lu, SU Ming-hua, LIANG Huan, HU Bo-bin, HUANG Jian-fang, CHEN Yan-hong, JIANG Jian-ning

Department of Infectious Diseases, the First Affiliated Hospital of Guangxi Medical University; Key Laboratory of High-Incidence-Tumor Prevention and Treatment, Ministry of Education, Nanning 530021

Received:2022-08-27 Online:2023-03-31 Published:2023-08-28
Contact: JIANG Jian-ning, Email: jjianning@163.com

摘要/Abstract

摘要： 目的观察高病毒载量慢性乙型肝炎孕妇口服核苷(酸)类抗病毒药母婴阻断的效果和安全性。方法从广西医科大学第一附属医院感染性疾病科慢性HBV感染随访队列中,选取HBV DNA≥1×10⁶ 拷贝/mL的慢性乙型肝炎孕妇411例,根据孕期有无口服抗病毒药分为阻断组256例、对照组155例,所有婴儿出生后均按标准接种乙肝疫苗和乙肝免疫球蛋白。分别比较阻断组服药基线、临产前、产后3个月的HBV DNA、ALT、AST水平,比较阻断组和对照组临产前HBV DNA水平和分娩婴儿7月至1岁龄的HBsAg阳性率。结果阻断组孕妇临产前DNA、ALT、AST水平低于服药基线分别为(3.16±1.05) lg拷贝/mL比(7.09±0.77)lg拷贝/mL、(21.90±12.00) U/L比(66.08±89.35) U/L、(29.16±9.16) U/L比(52.12±54.97) U/L,差异均有统计学意义(t=61.287、7.409、5.764,均P＜0.01)。阻断组孕妇临产前HBV DNA和婴儿HBsAg阳性率低于对照组 (3.16±1.05) lg拷贝/mL比(6.96±0.78) lg拷贝/mL、0.00%比9.68%,差异均有统计学意义(t=38.860,χ²=25.713,均P＜0.01)。阻断组和对照组均无围生期不良事件的报告。产后停服抗病毒药的产妇HBV DNA、ALT、AST水平高于产后继续服抗病毒药者分别为(6.70±1.39) lg拷贝/mL比(2.24±0.54) lg拷贝/mL、(54.19±50.00) U/L比(34.62±20.04) U/L、(42.50±28.04) U/L比(33.40±11.66) U/L,差异均有统计学意义(t=33.787、3.985、3.284,均P＜0.01)。结论高病毒载量的慢性乙型肝炎孕妇孕期口服核苷(酸)类抗病毒药联合婴儿接种乙肝疫苗和HBIG的“三重阻断”措施、产后患者继续抗病毒治疗,能成功阻断HBV母婴传播,保障孕期、产后母婴安全。

关键词: 慢性乙型肝炎, 高病毒载量, 母婴阻断, 妊娠, 核苷(酸)类抗病毒药

Abstract: Objective To investigate the effect and safety of nucleos(t)ide analogues (NAs) in hepatitis B virus (HBV) mother-to-infant obstruction of pregnant women with high viral load, and to provide real-world clinical data for interrupting mother-to-child transmission of HBV. Methods A total of 411 pregnant women with HBV DNA≥1×10⁶ copies/mL were retrospectively selected from the follow-up cohort of chronic HBV infection in our hospital, and they were divided into preventing group (256 cases) and control group (155 cases) according to the oral administration of NAs during pregnancy. All infants were vaccinated with hepatitis B vaccine and hepatitis B immunoglobulin as standard after birth. The levels of HBV DNA, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the preventing group were compared at baseline. before delivery and 3 months after delivery. The levels of HBV DNA before delivery and hepatitis B surface antigen (HBsAg) positive rate in infants from 7 months to 1 year were compared between 2 groups. Results The levels of DNA, ALT and AST before delivery were lower than baseline in the preventing group [(3.16 ± 1.05) log₁₀ copies/mL vs. (7.09 ± 0.77) log₁₀ copies/mL, P＜0.01; (21.90 ± 12.00) U/L vs. (66.08 ± 89.35) U/L, P＜0.01; (29.16 ± 9.16) U/L vs. (52.12 ± 54.97) U/L, P＜0.01]. The level of HBV DNA before delivery and the positive rate of HBsAg of infants in the preventing group were lower than those in the control group [(3.16 ± 1.05) log₁₀ copies/mL vs. (6.96 ± 0.78) log₁₀ copies/mL, P＜0.01; 0.00% vs 9.68%, P＜0.01]. No perinatal adverse events were reported in both groups. The levels of HBV DNA, ALT and AST in parturients who stopped taking NAs after delivery were higher than those who continued taking NAs [(6.70 ± 1.39) log₁₀ copies/mL vs. (2.24 ± 0.54) log₁₀ copies/mL, P＜0.01; (54.19 ± 50.00) U/L vs. (34.62 ± 20.04) U/L,P＜0.01; (42.50 ± 28.04) U/L vs. (33.40 ± 11.66) U/L, P＜0.01]. Conclusion The combination of oral NAs, hepatitis B vaccination and HBIG during pregnancy for pregnant women with high viral load and continued antiviral treatment for postpartum patients can successfully interrupt mother-to-child transmission of HBV and ensure the safety of mother and child during pregnancy and postpartum.

Key words: Chronic hepatitis B, High viral load, Mother-to-infant obstruction, Pregnancy, Nucleos(t)ide analogues

梁蘅恺, 韦璐, 苏明华, 梁焕, 胡伯斌, 黄建芳, 陈艳红, 江建宁. 高病毒载量慢性乙型肝炎孕妇口服核苷(酸)类抗病毒药母婴阻断的有效性和安全性[J]. 肝脏, 2023, 28(3): 296-298.

LIANG Heng-kai, WEI Lu, SU Ming-hua, LIANG Huan, HU Bo-bin, HUANG Jian-fang, CHEN Yan-hong, JIANG Jian-ning. Clinical study on the efficacy and safety of oral nucleos(t)ide analogues in HBV mother-to-infant obstruction of pregnant women with high viral load[J]. Chinese Hepatolgy, 2023, 28(3): 296-298.

参考文献

[1] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 中华传染病杂志, 2019, 37(12): 711-736.
[2] 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会. 乙型肝炎病毒母婴传播预防临床指南(2020). 中华妇产科杂志, 2020, 55(5): 291-299.
[3] 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会. 阻断乙型肝炎病毒母婴传播临床管理流程(2021年). 中华传染病杂志, 2021, 39(3): 139-144.
[4] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68(4): 672-681.
[5] Yim HJ, Kim IH, Suh SJ, et al. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. J Viral Hepat, 2018, 25(11): 1321-1330.
[6] Chen HL, Wen WH, Chang MH. Management of pregnant women and children: focusing on preventing mother-to-infant transmission. J Infect Dis, 2017, 216(suppl_8): S785-S791.
[7] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版). 临床肝胆病杂志, 2015, 31(12): 1941-1960.
[8] Kang Y, Cai Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy. J Hosp Infect, 2017, 96(4): 342-348.
[9] 张宝芳, 程明亮, 张权, 等. 贵州地区HBeAg阳性乙型肝炎病毒高载量孕妇母婴阻断的临床研究. 中华肝脏病杂志, 2018, 26(12): 945-950.
[10] 沈国俊, 岳涛, 陶一蕾, 等. 替诺福韦阻断孕晚期HBV母婴传播的疗效及停药安全性. 肝脏, 2019, 24(1): 63-65.
[11] 周娟, 刘月合, 王春佟. 应用替比夫定和替诺福韦治疗阻断血清HBV DNA高载量孕妇母婴传播的效果分析. 实用肝脏病杂志, 2020, 23(6): 805-808.
[12] Takano T, Tajiri H, Hosono S, et al. Natural history of chronic hepatitis B virus infection in children in Japan: a comparison of mother-to-child transmission with horizontal transmission. J Gastroenterol, 2017, 52(9): 1041-1050.
[13] Kim DY, Lee HW, Song JE, et al. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. J Med Virol, 2018, 90(3): 497-502.
[14] Yang QQ, Zhong ZH, Yang YL, et al. Efficacy and safety of tenofovir in the prevention of perinatal transmission of hepatitis B, a meta-analysis. Gastroenterol Hepatol, 2020, 43(10): 640-648.
[15] Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis, 2021, 21(1): 70-84.
[16] 邓勇, 郭丽霞, 李朝亮, 等. 替比夫定和替诺福韦阻断乙型肝炎病毒母婴传播的疗效和安全性meta分析. 肝脏, 2021, 26(1): 22-26.
[17] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370–398.
[18] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
[19] Hu Y, Xu C, Xu B, et al. Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study. J Viral Hepat, 2018, 25(4): 429-437.